Biocon Overview
- Year Founded
-
1978
- Status
-
Public
- Employees
-
9,811
- Stock Symbol
-
532523
- Investments
-
20
- Share Price
-
$3.88
- (As of Thursday Closing)
Biocon General Information
Description
Biocon Ltd is a biopharmaceutical company engaged in the manufacture of biotechnology products, active pharmaceutical ingredients, and formulations, including biosimilar drugs for diabetes, oncology, autoimmune diseases, and ophthalmology, as well as research services. The Company focuses on the core therapeutic areas of diabetes, oncology and immunology. Its segments are Generics, Biosimilars, and CRDMO, with Biosimilars generating the maximum revenue. The Company also complies with Extended Producer Responsibility (EPR) obligations by integrating EPR considerations into packaging design, procurement practices, and vendor engagement processes. The Company generates a majority of its revenue from customers located in India, and the rest from Brazil, Singapore, and the rest of the world.
Contact Information
Website
www.biocon.comCorporate Office
- 20th KM, Hosur Road
- Electronic City
- Bengaluru, Karnataka 560100
- India
Corporate Office
- 20th KM, Hosur Road
- Electronic City
- Bengaluru, Karnataka 560100
- India
Biocon Timeline
Biocon Stock Performance
As of 19-Nov-2026, Biocon’s stock price is $3.88. Its current market cap is $6.35B with 1.64B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.88 | $3.87 | $3.36 - $4.65 | $6.35B | 1.64B | 453K | $0.03 |
Biocon Financials Summary
As of 30-Sep-2026, Biocon has a trailing 12-month revenue of $1.87B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 7,738,610 | 7,886,649 | 7,031,130 | 6,143,879 |
| Revenue | 1,865,216 | 1,898,958 | 1,780,120 | 1,714,762 |
| EBITDA | 366,343 | 368,251 | 514,752 | 471,953 |
| Net Income | 48,760 | 43,638 | 119,836 | 123,511 |
| Total Assets | 6,796,323 | 6,746,036 | 6,873,718 | 6,723,629 |
| Total Debt | 1,634,316 | 1,635,790 | 2,146,616 | 1,951,795 |
Biocon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biocon Comparisons
Industry
Financing
Details
Biocon Competitors (37)
One of Biocon’s 37 competitors is Lupin, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lupin | Corporation | Mumbai, India | ||||
| Cipla | Corporation | Mumbai, India | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Aurobindo Pharma | Corporation | Hyderabad, India |
Biocon Patents
Biocon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026139792-A1 | Peptide drugs in a reusable pen | Pending | 23-Dec-2024 | ||
| WO-2025262552-A1 | Purification of gip/ glp-1 dual agonist peptides | Pending | 17-Jun-2024 | ||
| EP-4655312-A1 | A process for the preparation of glucagon | Pending | 27-Jan-2023 | ||
| US-20260042810-A1 | A process for the preparation of glucagon | Pending | 27-Jan-2023 | ||
| WO-2024157198-A1 | A process for the preparation of glucagon | Inactive | 27-Jan-2023 | C07K14/605 |
Biocon Signals
Biocon Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biocon Investments & Acquisitions (20)
Biocon’s most recent deal was a Secondary Transaction - Private with Ampin C&I Power Twelve for . The deal was made on 10-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ampin C&I Power Twelve | 10-Jun-2026 | Secondary Transaction - Private | Energy Production | ||
| Pro-zeal Green Power Sixteen | 31-Jan-2026 | Corporate | Energy Infrastructure | ||
| Biocon Biologics | 21-Jan-2026 | Secondary Transaction - Private | Drug Discovery | ||
| Eywa Pharma (New Jersey facility) | 02-Sep-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Mylan (Biosimilar Businesses) | 29-Nov-2022 | Merger/Acquisition | Pharmaceuticals |
Biocon ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
27.39 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Biocon Exits (2)
Biocon’s most recent exit was on 30-Sep-2009 from IDL Specialty Chemicals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| IDL Specialty Chemicals | 30-Sep-2009 | Completed |
|
||
| axicorp | 11-Feb-2008 | Merger/Acquisition | Completed |
Biocon Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Syngene International | Bangalore, India | 1993 | |
| Biocon Biologics | Bengaluru, India | 1978 |
Biocon FAQs
-
When was Biocon founded?
Biocon was founded in 1978.
-
Where is Biocon headquartered?
Biocon is headquartered in Bengaluru, India.
-
What is the size of Biocon?
Biocon has 9,811 total employees.
-
What industry is Biocon in?
Biocon’s primary industry is Drug Discovery.
-
Is Biocon a private or public company?
Biocon is a Public company.
-
What is Biocon’s stock symbol?
The ticker symbol for Biocon is 532523.
-
What is the current stock price of Biocon?
As of 19-Nov-2026 the stock price of Biocon is $3.88.
-
What is the current market cap of Biocon?
The current market capitalization of Biocon is $6.35B.
-
What is Biocon’s current revenue?
The trailing twelve month revenue for Biocon is $1.87B.
-
Who are Biocon’s competitors?
Lupin, Cipla, GSK, Glenmark Pharmaceuticals, and Aurobindo Pharma are some of the 37 competitors of Biocon.
-
What is Biocon’s annual earnings per share (EPS)?
Biocon’s EPS for 12 months was $0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process